

UCSF Helen Diller Family
Comprehensive
Cancer Center

December 12, 2013

Andrew H. Ko, M.D.
Associate Professor

Gastrointestinal Oncology
Division of Hematology/Oncology

University of California,
San Francisco
1600 Divisadero Street, 4th Floor
UCSF Box 1705
San Francisco, CA 94115
Office: 415-353-7286
Fax: 415/353-9931
[andrewko@medicine.
ucsf.edu](mailto:andrewko@medicine.ucsf.edu)

Dear Editors:

Please find enclosed the edited manuscript in Word format (file name: 6398-review (12.11.2013).docx) with requested changes.

Title: Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?

Authors: Evan J. Walker, Andrew H. Ko

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 6398

1. Table formatting has been updated per draft edits.
2. We appreciate the reviewers' helpful comments, and believe our manuscript has been improved according to their suggestions (key revisions highlighted in yellow in the revised manuscript):
 - a. Per reviewer 1, the systematic literature review by Rahma et al (Ann Oncology 2013) is now referenced in the Discussion section (reference 75).
 - b. Per reviewer 1, a new table (Table 5) is now including that lists all ongoing randomized phase II/III trials in the second-line setting for advanced pancreatic cancer.
 - c. Per reviewer 2, data from the trial of temsirolimus by Javle et al (reference 64) has been added to Table 4.
 - d. Per reviewer 3, consideration of cost effectiveness and quality of life endpoints in pancreatic cancer trials is now emphasized in the last paragraph of the Discussion section.
3. References are updated. A file including all references without a PMID (notably abstracts) has been uploaded under the 'Image Files' section.

Thank you again for publishing our invited manuscript in the World Journal of Gastroenterology.

Yours truly,



Andrew H. Ko, MD